These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 4113388)

  • 21. [Antituberculous activity of capreomycin and cross resistance to kanamycin, capreomycin and viomycin. 1. In vitro effects of capreomycin on Mycobacterium and the survival of tuberculous mice treated with capreomycin].
    Tanaka K; Saiga S
    Bull Chest Dis Res Inst Kyoto Univ; 1969 Sep; 3(1):36-43. PubMed ID: 5401218
    [No Abstract]   [Full Text] [Related]  

  • 22. [Cross-resistance relationship among capreomycin, kanamycin, viomycin and streptomycin resistance of Mycobacterium tuberculosis].
    Tsukamura M; Toyama H; Mizuno S; Tsukamura S
    Kekkaku; 1967 Oct; 42(10):399-404. PubMed ID: 4295935
    [No Abstract]   [Full Text] [Related]  

  • 23. [Interactions of antitubercular drugs. II. Combined effects of rifampin, ethambutol, capreomycin, viomycin, ethionamide and cycloserine on mycobacterial growth in vitro].
    Janowiec M; Zwolska-Kwiek Z
    Pneumonol Pol; 1983 Dec; 51(12):607-12. PubMed ID: 6199778
    [No Abstract]   [Full Text] [Related]  

  • 24. X-amidinotransferase in viomycin biosynthesis.
    Raczyńska-Bojanowska K; Tyc M; Paśś L; Kotula Z
    Bull Acad Pol Sci Biol; 1969; 17(4):203-8. PubMed ID: 4308132
    [No Abstract]   [Full Text] [Related]  

  • 25. Antibacterial activity of palmitoyltuberactinamine N and di-beta-lysylcapreomycin IIA.
    Yamada T; Yamanouchi T; Ono Y; Nagata A; Wakamiya T; Teshima T; Shiba T
    J Antibiot (Tokyo); 1983 Dec; 36(12):1729-34. PubMed ID: 6198315
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Anti-bacterial activity of capreomycin, kanamycin, or viomycin against drug-resistant tubercle bacilli isolated from patients].
    Endo K
    Jpn J Antibiot; 1971 Jun; 24(3):149-51. PubMed ID: 4327336
    [No Abstract]   [Full Text] [Related]  

  • 27. A Bartter's-like syndrome from capreomycin, and a similar gentamicin tubulopathy.
    Steiner RW; Omachi AS
    Am J Kidney Dis; 1986 Mar; 7(3):245-9. PubMed ID: 2420173
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Molecular analysis of kanamycin and viomycin resistance in Mycobacterium smegmatis by use of the conjugation system.
    Taniguchi H; Chang B; Abe C; Nikaido Y; Mizuguchi Y; Yoshida SI
    J Bacteriol; 1997 Aug; 179(15):4795-801. PubMed ID: 9244267
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effect of viomycin on dihydrostreptomycin binding to bacterial ribosomes.
    Masuda K; Yamada T
    Biochim Biophys Acta; 1976 Jul; 435(4):333-9. PubMed ID: 60132
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Critical concentrations for resistances of tubercle bacilli to tuberactinomycin-N, viomycin, capreomycin, and lividomycin in patients treated with these agents (cross-resistance-relationships among resistances to aminoglucoside-antibiotics found during chemotherapy for tuberculosis) (author's transl)].
    Tsukamura M; Mizuno S; Murata H; Oshima T
    Kekkaku; 1975 May; 50(4-5):123-30. PubMed ID: 49449
    [No Abstract]   [Full Text] [Related]  

  • 31. [Activities of rifampicin, capreomycin, viomycin or kanamycin against Mycobacterium tuberculosis isolated from tuberculosis patients].
    Endo K
    Jpn J Antibiot; 1970 Aug; 23(4):387-9. PubMed ID: 4321638
    [No Abstract]   [Full Text] [Related]  

  • 32. [Effects of streptomycin-resistance of Mycobacterium tuberculosis on induction rate of resistance to kanamycin, viomycin and capreomycin and on cross-resistance among these drugs].
    Nagata A; Mase M; Yamamoto M; Nakamura H
    Kekkaku; 1969 Jun; 44(6):173-9. PubMed ID: 4308767
    [No Abstract]   [Full Text] [Related]  

  • 33. Studies on viomycin. XIV. Roles of basic and cyclic moieties in the antimicrobial activity of viomycin.
    Kitagawa T; Miura T; Kurose H
    Chem Pharm Bull (Tokyo); 1979 Nov; 27(11):2551-6. PubMed ID: 230912
    [No Abstract]   [Full Text] [Related]  

  • 34. Studies on viomycin. VIII. Selective modifications of the terminal amino groups of viomycin.
    Kitagawa T; Miura T; Takaishi M; Taniyama H
    Chem Pharm Bull (Tokyo); 1975 Sep; 23(9):2123-7. PubMed ID: 171092
    [No Abstract]   [Full Text] [Related]  

  • 35. Studies on viomycin IX. Amino acid derivatives on viomycin.
    Kitagawa T; Miura T; Takaishi C; Taniyama H
    Chem Pharm Bull (Tokyo); 1976 Jun; 24(6):1324-30. PubMed ID: 191204
    [No Abstract]   [Full Text] [Related]  

  • 36. Studies on viomycin. VII. Oxidative modifications of viomycin.
    Kitagawa T; Miura T; Sawada Y; Fujiwara K; Ito R
    Chem Pharm Bull (Tokyo); 1974 Aug; 22(8):1827-34. PubMed ID: 4371987
    [No Abstract]   [Full Text] [Related]  

  • 37. [Experimental and clinical study test of capreomycin].
    Kozlova NV; Dzhumaev B; Stepanian ES; Kaminskaia GO
    Antibiotiki; 1976 Jul; 21(7):650-4. PubMed ID: 60080
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The structure of viomycidine.
    Büchi G; Raleigh JA
    J Org Chem; 1971 Apr; 36(7):873-7. PubMed ID: 4323751
    [No Abstract]   [Full Text] [Related]  

  • 39. Cross-resistance relationships between capreomycin, kanamycin, and viomycin resistances in tubecle bacilli from paients.
    Tsukamura M
    Am Rev Respir Dis; 1969 May; 99(5):780-2. PubMed ID: 4306213
    [No Abstract]   [Full Text] [Related]  

  • 40. Catalytic hydrogenation of viomycin and capreomycin.
    Dyer JR; Carter JH; van Wyk PJ
    J Med Chem; 1971 Nov; 14(11):1120-1. PubMed ID: 4329900
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.